Physician profile
Jason P Gamble
NPI 1396724613
$1,810.34
in general payments reported to CMS, 2019-2025
21 companies · $857 in 2025
The $857 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34.19 · 2020: $44.09 · 2022: $54.65 · 2023: $187 · 2024: $634 · 2025: $857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,677.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,677.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $252.62 | 2023-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $241.73 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Insmed, INC. | $205.28 | 2024-2025 | Arikayce, Brinsupri |
| Amgen INC. | $200.12 | 2023-2025 | Krystexxa, Repatha, Otezla |
| Pfizer INC. | $194.18 | 2023-2025 | |
| Glaxosmithkline, LLC. | $108.02 | 2019-2025 | Shingrix, Arexvy, Nucala |
| La Jolla Pharmaceutical Company | $105.88 | 2024-2025 | Xacduro, Zevtera, Giapreza |
| Novartis Pharmaceuticals Corporation | $62.97 | 2019-2020 | |
| Mylan Specialty L.P. | $55.45 | 2024 | Yupelri |
| Janssen Pharmaceuticals, INC | $54.65 | 2022 | |
| Lilly USA, LLC | $52.47 | 2025 | Mounjaro |
| Abbvie INC. | $48.57 | 2023-2024 | |
| Boston Scientific Corporation | $41.30 | 2023-2025 | General - Pain Management, Watchman Access System |
| Abbott Laboratories | $40.75 | 2024 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $31.72 | 2024-2025 | Capvaxive, Gardasil, Gardasil 9 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $25.80 | 2024 | Heplisav-B |
| Phathom Pharmaceuticals, INC. | $19.46 | 2024 | Voquezna |
| Axsome Therapeutics, INC. | $18.04 | 2025 | Auvelity |
| Exact Sciences Corporation | $17.97 | 2025 | Cologuard Collection Kit |
| Viatris Specialty LLC | $17.88 | 2025 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.48 | 2025 | Relistor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Gamble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.